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Abstract
Approximately 5% of all breast cancers are due to one of the high-risk breast cancer genes
BRCA1 and BRCA2, or possibly to a third or fourth moderate- to high-risk gene(s). A further
proportion of cases arise in the presence of a less striking family history, with later average
age at onset and lower penetrance: familial breast cancer. Bilaterality is a recognized feature
of hereditary breast cancer. Cancers often present at an early age, with the contralateral risk
high within 10 years. Proof that bilateral malignancies are separate primaries can be difficult
histologically, however, especially within 3 years. The recent finding of specific pathological
features related to BRCA1 and, to a lesser extent, BRCA2 mutations means that, in addition
to bilaterality and family history, a pathological element can be entered into the risk
calculation for the presence of BRCA1/BRCA2 mutations. This will facilitate the targeting of
mutation testing to families in which a positive result is most likely, and may subsequently
influence the clinical management of these families.
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Breast cancer genetics
A number of genes have been identified during the past 10
years which, when inherited in a mutant form, confer a high
lifetime risk for breast cancer and for a spectrum of other
cancers. These genes are not common and together are esti-
mated to occur in a mutated form in about one in 300 indi-
viduals in the general population [1•,2], and to account for
about 5% of all breast cancers. The proportion of young
breast cancers accounted for by these high-risk genes is,
however, considerably higher [3]. In addition to these high-
risk susceptibility genes, there are also likely to be a number
of lower penetrance, more frequently occurring gene muta-
tions that increase breast cancer risk. These probably inter-
act significantly with epidemiological risk factors [4]. Few
such genes or polymorphisms have been identified as yet.
The breast cancer genes
BRCA1 was mapped to chromosome 17q in 1990 [5] and
the genetic sequence was published in 1994 [6], simulta-
neously with a report of the localization of a second major
susceptibility gene BRCA2 [7]. BRCA2 was cloned in 1995
[8]. These genes are both large and mutation analysis is
expensive and time consuming. Nonetheless, in families
with a high chance of a genetic predisposition, genetic
testing is offered in most Western genetics centres. Thus,
an increasing number of young women with a strong
family history of breast and ovarian cancer are undergoing
presymptomatic genetic testing.
Somatic mutations in the TP53 gene are extremely
common in all types of cancer. Inherited germline muta-http://breast-cancer-research.com/vol1no1/27oct99/review/5
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tions are, however, rare. The Li-Fraumeni syndrome
(LFS) represents the striking pattern of childhood malig-
nancy (typically soft tissue and osteosarcomas, gliomas or
adrenocortical carcinoma) and very early onset breast
cancer (50% of female gene carriers have developed breast
cancer by 30 years of age). Over 70% of classical LFS fam-
ilies have inherited TP53 mutations [9•]. There is good in-
vitro evidence to suggest that patients with LFS have an
abnormal response to low-dose radiation with defective
apoptosis [10]. Recognition of this syndrome is therefore
important, not least because it has implications for breast-
screening methods.
Other recently discovered genes that confer an increase in
risk of breast cancer and are associated with bilateral benign
and malignant breast disease are Cowden’s disease (due to
mutations in the PTEN gene [11]) and Peutz-Jehger syn-
drome (PJS; due to mutations in CDNK4 [12]). Both are
rare, and the lifetime risk of breast cancer is probably less
than 35%. Both these conditions have a distinct clinical
phenotype with a diagnosis possible on clinical grounds
(mucosal pigmentation in PJS; macrocephaly, scrotal tongue
and thyroid tumours in Cowden’s disease) and on pathology
of skin and gut tumours (typical hamartomas of the gut in
PJS and trichilemmomas in Cowden’s disease).
It is difficult to predict whether BRCA1 or BRCA2 muta-
tions are present in most families with multiple cases of
breast cancer. The presence of two or more ovarian
cancers in addition to two or more breast cancers diag-
nosed before the age of 60 years gives at least a 90% likeli-
hood of BRCA1 mutation, and male breast cancer plus
three or more breast cancers diagnosed before the age of
60 years gives an 80% risk of BRCA2 [13]. These particu-
lar families, however, represent less than 0.5% of all breast
cancer and probably less than 10% of all BRCA1/BCRA2
families. In particular, families with only two or three
breast cancers diagnosed before the age of 60 years have a
relatively small risk of a BRCA1/BRCA2 mutation, and the
majority of the hereditary element is due to other, as yet
unidentified, genes [13]. Therefore, information from the
breast cancer pathology may help prioritize those families
in which genetic screening of BRCA1/BRCA2 would be
most useful.
Pathology of hereditary breast cancer
Hereditary breast cancer has some interesting biological
differences compared with apparently sporadic cancer. In
breast malignancies from patients with a BRCA1 mutation,
a greater proportion are high grade and histologically
medullary or atypical medullary in type [14,15•].
Therefore, in individuals with bilateral medullary/atypical
medullary cancer, the probability of BRCA1 mutation
should be very high. This will need to be confirmed by
further studies. At the present time, no other histopatho-
logical type is associated with mutations in particular sus-
ceptibility genes. Nonetheless, finding bilateral breast
cancers or multiple primary tumours will increase the
chance of hereditary disease.
Both lobular carcinoma in situ (LCIS) and atypical hyper-
plasia have been associated with family histories of breast
cancer [16,17]. The 10 year risk of invasive disease in asso-
ciation with family history is approximately 40% [17].
Skolnick  et al [16] suggested that persons with LCIS were
more likely to have a mother or sister with breast disease
than with other tumour types. The Breast Cancer Linkage
Consortium [15•], however, demonstrated that LCIS was
less common in carriers of BRCA1 and BRCA2 mutations
than in sporadic control individuals, although this did not
reach formal statistical significance. Skolnick et al [16] did
not find a significant statistical association between ductal
carcinoma in situ (DCIS) and family history. This was sup-
ported by the Breast Cancer Linkage Consortium data,
which found fewer cases of DCIS among BRCA1 mutation
carriers than among control individuals. The rate of DCIS
in BRCA2 mutation carriers was similar to that in sporadic
control individuals, however. It may be that proliferative
breast disease is a marker for BRCA3/BRCA4.
The evidence from histological studies for the association
of specific types of tumour with BRCA1 and BRCA2 muta-
tions will allow a directed approach to genetic testing of
breast cancer families.
The survival of women with breast cancers with known
mutations in BRCA1/BRCA2 is controversial. Early reports
based on families linked to BRCA1 [18] suggested that the
survival for these women was significantly better than that
in matched individuals with sporadic tumours. This study
had a survival bias, however; in order to ascertain large
families for genetic linkage, a number of women within
the family need to survive. Other studies have suggested
that the survival is worse in BRCA1 and BRCA2 mutation
carriers [19], or the same [20,21]. A more recent study [22]
of Ashkenazi Jews with mutations in BRCA1/BRCA2
demonstrated that carriers did not seem to have either a
better or worse prognosis. Larger prospective studies are
needed to answer fully the question of survival among this
group of women with breast cancer.
Genetic testing
A number of groups have reported on the likelihood of
finding BRCA1 and to a lesser extent BRCA2 mutations in
certain given situations with different family histories
[23,24]. The new information from breast pathologists will
almost certainly alter the approach. Although the chances
of finding a BRCA1 mutation in an individual with a spo-
radic breast cancer who is aged under 50 years is small
[25], this would alter significantly if medullary features
were found, particularly in the presence of a family historyBreast Cancer Research    Vol 1 No 1 Lalloo and Evans
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of breast or ovarian cancer. Most genetic testing occurs in
the context of an unaffected woman seeking advice about
her risks of breast cancer. Therefore, the pathology of the
breast cancers in her relatives will be relevant. Finding a
histology report with medullary features or that all the
breast cancers in the family were oestrogen receptor nega-
tive and grade 3 would heighten the chance of finding a
mutation in the family, thus enabling further management
guidance of the individual at risk. Even if the woman does
not want to know her own BRCA1/BRCA2 status [26•], she
may still want to take advantage of ovarian screening
because she would be at half the carrier risk for ovarian
cancer of 20–60% [2].
Breast cancer management
Once breast cancer develops in an individual, appropriate
management of that cancer is the primary consideration.
Because many of these patients are young and present
with early cancers, breast conservation is in many cases
technically possible. Wide local excision and axillary node
sampling (at least) with adjuvant radiotherapy might be
expected to produce equivalent results to simple mastec-
tomy if this disease is similar in all respects to sporadic
breast cancer. For a woman with either a proved or sus-
pected genetic susceptibility, the chance of recurrence
must take into account the background susceptibility of
the remaining breast tissue. This includes the risk of a
new primary in the contralateral breast. In order to discuss
this, an estimate of the risk involved is required. Because
familial cancers are more likely to be multifocal and bilat-
eral, the risk of a new primary on the treated side is likely
to be high without adjuvant therapy. There are very little
data on the conservative management of BRCA1/BRCA2
mutation carriers compared with those with sporadic
disease, although the outcome of breast conservation in a
small number of hereditary versus sporadic early age
breast cancers in an American cohort [27] has been
reported. At present, there is no clear contraindication to
breast conservation for the affected breast.
Management of the contralateral breast
The risk to the contralateral breast for a woman with
breast cancer and a hereditary predisposition approaches
50% at 10 years [28]. The greatest chance of recurrence of
breast cancer, either locoregional or metastatic, is in the
first 2 years after diagnosis. Given the high contralateral
risk, many women with a BRCA1/BRCA2 mutation (or a
high risk for carrying a mutation) may opt for prophylactic
removal of the contralateral breast in addition to mastec-
tomy for the ipsilateral side. A further option is close sur-
veillance of the remaining breast tissue. Screening for
early breast cancer is of uncertain benefit in terms of a
clear reduction in mortality, however [29,30], although
early cancers can undoubtedly be detected [31–33]. Con-
ventional mammographic screening may be less sensitive
in the younger breast [30], but this remains unclear.
Screening for breast cancer
Whereas screening by mammography has been accepted
in the UK for women over the age of 50 years [34], screen-
ing under this age is still controversial. A number of
studies [31,33] suggest that screening women with a
family history of breast or ovarian cancer is of use. If a
woman has bilateral medullary carcinoma of the breast,
even in the absence of any further family history, it
becomes likely that the malignancy is due to a BRCA1
mutation. Unaffected women in this type of family should
then be offered mammographic screening. Because
tumours associated with BRCA1 mutations are highly pro-
liferative, screening intervals would have to be adjusted to
avoid interval cancers. The pathology of breast cancers can
therefore be used to direct clinical screening of families as
well as genetic screening.
Further studies
We would suggest that the following studies should be
undertaken in the future in order to clarify further the cor-
relation between breast cancer pathology and family
history/BRCA mutations:
(1) a long term prospective study of the pathology of breast
tumours in families with known BRCA mutations;
(2) analysis of BRCA1 in an unselected series of
medullary carcinoma;
(3) assessment of families with proliferative breast
disease for the potential involvement of future BRCA
genes; and
(4) The inclusion of pathology data into the risk evalua-
tion equation in families already tested for BRCA1/
BRCA2 mutations.
Conclusion
Although options for women diagnosed with breast cancer
in the presence of a family history may seem limited and
the evidence to support each option relatively thin, many
women recently diagnosed are now requesting genetic
tests to guide their decisions and those of their family.
The pathology of their breast cancer may give further
useful information in deciding which samples represent a
high priority for genetic testing.
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